Rani Therapeutics Holdings, Inc.

NASDAQ
RANI
Stock
Yield per half year: -69.49%
Dividend yield: 0%
Sector: Healthcare

0.6071 $

-0.0136 $ -2.19%
0.4817 $
4.39 $

Min/max per year

Share chart Rani Therapeutics Holdings, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Rani Therapeutics Holdings, Inc.

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including large molecules, such as peptides, proteins, and antibodies.

more details
Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The company was incorporated in 2012 and is headquartered in San Jose, California.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Main settings

IPO date
2021-07-30
ISIN
US7530181004
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
link
All parameters

Grade

Underestimation
Title Value Grade
P/S 0 0
P/BV 3.31 5
P/E 0 0
Efficiency
Title Value Grade
ROA -58.65 0
ROE -264.03 0
ROIC 0 0
Dividends
Title Value Grade
Dividend yield 0 0
DSI 0 0
Average dividend growth 0 0
Debt
Title Value Grade
Debt/EBITDA -0.4611 10
Debt/Ratio 0.5197 9
Debt/Equity 1.28 8
Growth impulse
Title Value Grade
Yield Revenue, % 175.79 10
Yield Ebitda, % 150.1 10
Yield EPS, % -6.2 0
More

Prices

Price Min. Max. Change Changes in the industry Changes in the index
Yesterday 0.6207 $ 0 $ 0 $ -2.19 % 0 % 0 %
Week 0.7082 $ 0 $ 0 $ -14.28 % 0 % 0 %
Month 1.1 $ 0.4817 $ 0.776 $ -44.81 % 0 % 0 %
Three month 1.54 $ 0.4817 $ 1.55 $ -60.58 % 0 % 0 %
Half a year 1.99 $ 0.4817 $ 1.93 $ -69.49 % 0 % 0 %
Year 5 $ 0.4817 $ 4.39 $ -87.86 % 0 % 0 %
3 years 10.89 $ 0.4817 $ 12.43 $ -94.43 % 0 % 0 %
5 years 0 $ 0.4817 $ 35 $ 0 % 0 % 0 %
10 years 0 $ 0.4817 $ 35 $ 0 % 0 % 0 %
Year to date 1.42 $ 0.4817 $ 1.85 $ -57.25 % 0 % 0 %

Main owners

Similar companies

P/E & P/BVEV/Ebitda & Debt/Ebitda


Company management

Head Job title Payment Year of birth
Mr. Mir A. Imran Executive Chairman 80k 1956 (69 years)
Mr. Talat Imran CEO & Director 450k 1982 (43 years)
Mr. Svai S. Sanford Chief Financial Officer 416k 1970 (55 years)
Dr. Mir Hashim Chief Scientific Officer 416k 1960 (65 years)
Mr. Eric Groen General Counsel N/A 1971 (54 years)
Ms. Bella Vazquez Vice President of Human Resources N/A
Ms. Kate McKinley M.B.A. Chief Business Officer N/A 1977 (48 years)
Ms. Arvinder Dhalla Vice President of Clinical Development N/A

About company

Address: United States, San Jose. CA, 2051 Ringwood Avenue - Open in google maps, Open in yandex maps
Website: https://www.ranitherapeutics.com